Publication

Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial

Karimi, Y.
; 
Ghesquieres, H.
; 
Jurczak, W.
; 
Cheah, C.
; 
Clausen, M.
; 
Lugtenburg, P.
; 
Cunningham, D.
; 
Do, Y. R.
; 
Lewis, D. J.
; 
Gasiorowski, R.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Karimi, Y.
Ghesquieres, H.
Jurczak, W.
Cheah, C.
Clausen, M.
Lugtenburg, P.
Cunningham, D.
Do, Y. R.
Lewis, D. J.
Gasiorowski, R.
Kim, T. M.
Van der Poel, M.
Poon, M. L. M.
Feldman, T. A.
Linton, Kim M
Sureda, A.
Hutchings, M.
Stirner, M. C.
Sacchi, M.
Thieblemont, C.
Affiliation
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003468.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626652
Embedded videos